Eton Pharmaceuticals (ETON) Set to Announce Quarterly Earnings on Thursday

Key Points

• Eton Pharmaceuticals is expected to report Q3 2026 earnings after market close on November 5. Analysts forecast earnings of $0.3125 per share and revenue of $41.98 million; the company previously beat estimates with $0.43 EPS and $37.59 million in revenue.
• ETON shares opened at $51.80, with a market capitalization of $1.48 billion and a notably high P/E ratio of 136.32. The stock has traded between $14.27 and $66.37 over the past year.
• Analysts maintain a favorable outlook, with a consensus “Buy” rating and a $71.50 price target, although insiders sold 79,166 shares worth approximately $4.81 million during the last quarter.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) is expected to announce its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of $0.3125 per share and revenue of $41.98 million for the quarter. Interested persons can find conference call details on the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported $0.43 EPS for the quarter, beating analysts' consensus estimates of $0.19 by $0.24. The firm had revenue of $37.59 million for the quarter, compared to the consensus estimate of $27.11 million. Eton Pharmaceuticals had a net margin of 12.02% and a return on equity of 40.13%. On average, analysts expect Eton Pharmaceuticals to post $1.13 EPS for the current fiscal year and $1.94 EPS for the next fiscal year.

Eton Pharmaceuticals Price Performance

Shares of ETON stock opened at $51.80 on Thursday. The firm has a fifty day moving average of $56.32 and a two-hundred day moving average of $35.19. The firm has a market cap of $1.48 billion, a P/E ratio of 136.32 and a beta of 0.90. Eton Pharmaceuticals has a 1-year low of $14.27 and a 1-year high of $66.37. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.52 and a quick ratio of 1.30.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ETON. Zacks Research upgraded shares of Eton Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Monday, October 12th. Weiss Ratings upgraded Eton Pharmaceuticals from a "sell (d-)" rating to a "hold (c)" rating in a research note on Tuesday, September 22nd. HC Wainwright reissued a "buy" rating and issued a $70.00 price objective on shares of Eton Pharmaceuticals in a report on Wednesday, October 14th. B. Riley Financial reissued a "buy" rating and issued a $70.00 price objective (up from $40.00) on shares of Eton Pharmaceuticals in a report on Friday, August 14th. Finally, Craig Hallum restated a "buy" rating and set a $78.00 price objective on shares of Eton Pharmaceuticals in a research note on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $71.50.

Insider Activity

In other news, Director Paul V. Maier sold 50,000 shares of the business's stock in a transaction on Friday, August 28th. The shares were sold at an average price of $59.07, for a total transaction of $2,953,500.00. Following the completion of the transaction, the director owned 59,745 shares of the company's stock, valued at approximately $3,529,137.15. The trade was a 45.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider David Krempa sold 4,166 shares of Eton Pharmaceuticals stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $55.07, for a total transaction of $229,421.62. Following the completion of the sale, the insider owned 43,381 shares in the company, valued at approximately $2,388,991.67. This represents a 8.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 79,166 shares of company stock worth $4,809,672. 16.49% of the stock is owned by company insiders.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited therapeutic options. The company generally pursues products that address unmet medical needs, including medicines for pediatric and orphan indications.

Eton's commercial portfolio has included Alkindi Sprinkle, an oral hydrocortisone formulation used as replacement therapy in young children with adrenal insufficiency, and Eprontia, an oral solution formulation of topiramate.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.